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Tacrolimus-Induced Salt Losing Nephropathy
Resolved After Conversion to Everolimus
Burak Sayin, MD
Tacrolimus is one of the most commonly used immuno-suppressive drugs but tacrolimus-induced severe symp-
tomatic hyponatremia is not a well-documented issue in
kidney transplant patients.1-4 In our current report, we de-
scribe a case of tacrolimus-induced hyponatremia in a living
donor kidney recipient in whom any other potential cause
of hyponatremia was excluded, and tacrolimus-induced
salt losing nephropathy was resolved after conversion to
everolimus.
CASE REPORT
A 44-year-old male patient who received kidney trans-
plantation in June 2014 from his elder sister admitted to
emergency unit of Baskent University Ankara Hospital on
December 16 with complaints of anorexia, nausea,
vomiting, and headache. He had a serum creatinine level
of 1.26 mg/dL and a blood urea nitrogen level of 21 mg/dL.
He was found to have severe hyponatremia with a serum
sodium of 102 mmol/L and a moderately low potassium
level of 3.1 mmol/L. He was receiving losartan 100 mg/day
and karvedilol 25 mg/day for hypertensive treatment and tri-
ple immunosuppressive regimen of tacrolimus 2 mg/day, my-
cophenolate mofetil 1000 mg/day, and prednisolone
5 mg/day. In thyroid function tests, serum osmolality was in
the normal range, and this was his very first hyponatremic state
after the successful kidney transplantation.Hewas not receiving
any drugs that might result hyponatremia, such as diuretics or
parenteral fluids. His blood glucose level was 107 mg/dL, and
he had no sign of osmotic diuresis. Twenty-four–hour urinary
sodium excretion was 380 mmol/L, suggesting a salt-losing ne-
phropathy. He received 3% hypertonic NaCl 300 mL/day, but
serum sodium level only improved to 117 mmol/L after
48 hours. We suspected tacrolimus to be responsible for the
salt-losing state of the recipient and discontinued tacrolimus
and initiated everolimus 0.75 mg/12 hours. Forty-eight hours
after discontinuation of tacrolimus, his serum sodium level im-
proved to 132 mmol/dL with no need of more hypertonic
fluid replacement. Repeated 24-hour sodium excretion was
120 mmol/day. A mild increase of serum creatinine level of
1.42 mg/dL was observed after conversion to everolimus,
and all the symptoms due to hyponatremia were resolved.
During 2 months of follow-up after cessation of tacrolimus,
the serum sodium levels of our patient remained in the nor-
mal range, which showed that the delayed effect of hyper-
tonic saline and volume contraction was not responsible for
resolving of the hyponatremic state.
DISCUSSION
There are only few studies reporting tacrolimus-induced
salt-losing state after solid organ transplantation. Higgins
et al3 showed that patients on tacrolimus were more prone
to hyponatremia compared to patients receiving cyclospor-
ine. The patients who developed hyponatremia were not at-
tributed to any cause other than tacrolimus, but the median
time was 18 days after transplantation. In our case, the pa-
tient developed tacrolimus-induced symptomatic hypona-
tremia 154 days after transplantation and the tacrolimus
level was in the target range (5.3 ng/mL). Our patient had a
urine output of 1.5 to 2.8 L/day, which excludes hypo-
natremia according to posttransplant polyuria. Other suspi-
cious factors, such as hyperglycemia, hypothyroidism, use
of diuretics, parenteral hypotonic fluid administration, or
any drug other than tacrolimus that might cause hypo-
natremia, were all excluded.1-5
Tacrolimus is suggested to effect distal tubular Na-K-2Cl
cotransporter, which may result to salt-losing nephropathy
resistant to aldosterone. Therefore, fludrocortisone was re-
ported to be effective in tacrolimus-induced nephropathy.6
We are not able to report the response to fludrocortisone in
our patient because we decided to discontinue tacrolimus
and convert to everolimus to eliminate the effect of tacrolimus.
CONCLUSIONS
Tubular dysfunction and calcineurin inhibitor toxicity
may develop even in the target doses of tacrolimus, and
Received 11 April 2015. Revision received 26 June 2015.
Accepted 19 July 2015.
Nephrology Department, Baskent University, Ankara, Turkey.
The author declares no funding or conflicts of interest.
B.S. participated in research design and participated in the writing of the article.
Correspondence: Burak Sayin, Fevzi Cakmak Mah 5. Sokak No: 48 06640
Bahcelievler Cankaya Ankara, Turkey. (buraksayin@hotmail.com).
Copyright © 2015 The Authors. Transplantation Direct. Published byWolters Kluwer
Health, Inc. This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is per-
missible to download and share the work provided it is properly cited. The work can-
not be changed in any way or used commercially. http://creativecommons.org/
licenses/by-nc-nd/3.0.
ISSN: 2373-8731
Transplantation Direct 2015;1: e37; doi: 10.1097/TXD.0000000000000538.
Published online 19 October 2015
CaseStudyReport
Transplantation DIRECT ■ 2015 www.transplantationdirect.com 1
Copyright © 2015 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc.
resistant symptomatic hyponatremic state in a transplant pa-
tient receiving tacrolimus must be considered in differential
diagnosis of severe hyponatremia. Conversion to everolimus
in tacrolimus-induced hyponatremia may be a good alterna-
tive immunosuppressive regimen in kidney transplant recipi-
ents with salt-losing state.7,8
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